In a report released yesterday, Kseniia Maslova from UBS maintained a Hold rating on Rolls-Royce Holdings (RYCEF – Research Report), with a price target of £1.02. The company’s shares closed last Thursday at $1.02, close to its 52-week low of $0.95.
According to TipRanks.com, Maslova is ranked #5151 out of 7992 analysts.
Rolls-Royce Holdings has an analyst consensus of Hold, with a price target consensus of $1.23, implying a 19.5% upside from current levels. In a report released yesterday, Jefferies also maintained a Hold rating on the stock with a £0.90 price target.
Rolls-Royce Holdings’ market cap is currently $8.4B and has a P/E ratio of -3.60.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RYCEF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense, ITP Aero, and Corporate. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The ITP Aero segment provides aeronautical engines and gas turbines. The company was founded in March 1906 and is headquartered in London, the United Kingdom.
Read More on RYCEF:
- H.C. Wainwright Reiterates a Buy Rating on HIVE Blockchain Technologies (HIVE)
- UBS Thinks LANXESS’s Stock is Going to Recover
- H.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)
- H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)
- Canaccord Genuity Sticks to Its Buy Rating for Oklo Resources Limited (OKLOF)